Trobix Bio is advancing cutting-edge biotherapeutics to treat metabolic, inflammatory and cancer diseases, by developing orally administered products utilizing engineered phages, synthetic biology, and CRISPR technologies to secrete biotherapeutics from microbiome bacteria.
CRISPR-Cas3 drives in-vivo selection of TBX Cargo to generate a robust and durable therapeutic effect
Manipulating specific activities in targeted microbiome bacteria
Oral delivery of human biotherapeutics
Precise targeting with no disruption of the natural microbiome
Innovative unified core system for phage cocktail production